Loading
SP
SpyGlass Pharma, Inc. Stock: price and insider trades · United States
US·Mcap US$826.8M
No insider purchase over the last 90 days. The latest was filed 11 Feb 2026.
SpyGlass Pharma, Inc.: what insiders have been doing
This page follows insider dealings at SpyGlass Pharma, Inc. as filed with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 15 insiders published 15 filings.
Only purchases show up on the open market, 1 purchase in all worth €271k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 senior executive. At €271k, the purchase published on 11 February 2026 by Khan Bilal Arshad is the largest of the period.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 15 filings, this issuer sits below that mark. Our records for SpyGlass Pharma, Inc. go back to 2026, with 1 purchase and no sales on the open market in total.
The clock since the last published purchase (11 February 2026) now reads 249 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
15
Thresholds
n/a
Buy Volume
€270,595
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBilal Arshad Khan1 buy
Analyst consensus: bullish or bearish?
Analysts rate SpyGlass Pharma, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$44.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$24.72
Analyst consensus
6 analystsStrong buy
US$37.00Target US$44.00(+78%)US$62.00
Income statement
EBITDA-US$40.8M
Net income-US$39.9M0.0% margin
Valuation
PER (forward)-8.8x
P/Book3.6x
Balance sheet & cash
Market capUS$826.8M
Total debtUS$1.6M
Free Cash Flow-US$33.5M
Debt / Equity1%
Profitability & ownership
% insiders4.3%
% institutions94.7%
Last declaration on 11 February 2026
Declarations15 total
20,000 shares@ US$16.00100.0% of flowCommon StockSEC:0002108044-26-000006:0
Canonical exit: 10 May 2026 (T+90)
1,875,013 shares0Common StockSEC:0001753143-26-000006:0
2,524,473 sharesCommon StockSEC:0001231919-26-000135:0
1,619,240 sharesCommon StockSEC:0001193125-26-046676:0
1,619,240 sharesCommon StockSEC:0001193125-26-046674:0
1,619,240 sharesCommon StockSEC:0001193125-26-046673:0
1,619,240 sharesCommon StockSEC:0001193125-26-046671:0
1,619,240 sharesCommon StockSEC:0001193125-26-046668:0
1,619,240 sharesCommon StockSEC:0001193125-26-046666:0
1,619,240 sharesCommon StockSEC:0001193125-26-046664:0
1,619,240 sharesCommon StockSEC:0001193125-26-046663:0
1,619,240 sharesCommon StockSEC:0001193125-26-046662:0
1,690,230 sharesCommon StockSEC:0001193125-26-045029:0
1,690,230 sharesCommon StockSEC:0001193125-26-045028:0
15 of 15 declarations
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. is a pharmaceutical company focused on developing innovative treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
